Company: NDRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001654954-25-009643
Chunk: 3

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
-   -   -   -   -   -   424,087   -   -   424,087 Stock payable towards preference dividend  -   -   -   -   -   -   5,206   (5,206)  -   - Net loss  -   -   -   -   -   -   -   -   (5,004,853)  (5,004,853)Balance as of June 30,2024   17,488  $-   -  $-   41,394  $3  $105,928,916  $27  $(96,935,005) $8,993,941 

Six Months Ended June 30,2025  Series A Convertible  Series B Convertible       Additional      Total    Preferred Stock  Preferred Stock  Common stock  Paid in   Stock   Accumulated  Stockholders'    Shares   Amount   Shares   Amount   Shares   Amount   Capital  Payable  Deficit   Equity Balance as of December 31, 2024   17,488  $-   -  $-   536,908  $53  $105,998,412   -  $(103,438,099) $2,560,366 Common stock issued for cash  -   -   -   -   215,482   21   1,003,197   -   -   1,003,218 Fair value of vested stock options  -   -   -   -   -   -   132,279   -   -   132,279 Fair value of vested restricted stock units  -   -   -   -   -   -   39,530   -   -   39,530 Net loss  -   -   -   -   -   -   -   -   (2,262,242)  (2,262,242)